89581-64-6

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate is utilized as a building block in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and functional groups make it a valuable component in creating various medicinal and agricultural compounds.
Used in Organic Chemical Reactions:
methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate also serves as a reagent in organic chemical reactions, particularly in the formation of new carbon-carbon and carbon-nitrogen bonds. Its role in these reactions is crucial for the development of complex organic molecules and materials.
Safety Precautions:
Methyl 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylate can be potentially hazardous if not handled and stored properly. Therefore, it is essential to exercise caution when working with this chemical to ensure safety and avoid any adverse effects.

Upstream product

• 51149-08-7 3,6-dichloropyridazin-4-carboxylic acid 
• 286946-24-5 methyl 3,6-dichloropyridazine-4-carboxylate 
• 67-56-1 methanol 
• 50681-26-0 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid 

Downstream Products

• 1204400-37-2 C₁₃H₉ClF₂N₂O₃ 
• 1345443-39-1 C₁₃H₁₀F₂N₂O₄ 
• 1204400-38-3 C₁₂H₇ClF₂N₂O₃ 
• 89640-80-2 C₆H₆N₂O₃ 

Relevant academic research and scientific papers

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure-activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

1H - IMIDAZO [4, 5 - C] QUINOLINES

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the units W, A, L, Q1 and QH are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use as medicaments having the above-mentioned properties.